Related Experiment Video

Updated: Jun 19, 2025

Caspase-3 Activity in the Rat Amygdala Measured by Spectrofluorometry After Myocardial Infarction
08:41

Caspase-3 Activity in the Rat Amygdala Measured by Spectrofluorometry After Myocardial Infarction

Published on: January 12, 2016

11.7K

Treating Depression to Improve Survival in Coronary Heart Disease: What Have We Learned?

Robert M Carney1, Kenneth E Freedland1, Michael W Rich2

  • 1Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA.

Journal of the American College of Cardiology
|July 24, 2024
PubMed

Insights

Major depressive disorder increases cardiac event risk. Persistent insomnia, fatigue, and anhedonia, even after depression treatment, independently predict cardiac events in coronary heart disease patients.

Area of Science:

  • Cardiology
  • Psychiatry
  • Clinical Research

Background:

  • Major depressive disorder (MDD) is a known risk factor for cardiac events in patients with coronary heart disease (CHD).
  • Previous clinical trials show limited evidence that treating MDD improves cardiac event-free survival in these patients.

Purpose of the Study:

  • To review evidence suggesting that specific residual symptoms of depression, namely insomnia, fatigue, and anhedonia, independently predict cardiac events.
  • To propose that these persistent symptoms, rather than syndromal depression itself, may drive adverse cardiovascular effects in CHD patients.

Main Methods:

  • Review of existing clinical trial data and scientific literature.
  • Analysis of the independent predictive value of insomnia, fatigue, and anhedonia on cardiac events.

Main Results:

  • Certain symptoms like insomnia, fatigue, and anhedonia often persist after successful depression treatment.
  • These residual symptoms independently predict cardiac events in patients with CHD.
  • This finding may explain why previous trials failed to show improved cardiac outcomes despite depression symptom improvement.

Conclusions:

  • Adverse cardiovascular effects in CHD patients may be linked to persistent insomnia, fatigue, and anhedonia, irrespective of overall depression status.
  • Interventions targeting these specific symptoms are needed.
  • Further research is recommended to evaluate the effectiveness of interventions for these symptoms in depressed CHD patients.

Keywords:
anhedoniaantidepressive agentsdepressive disorder majorfatiguemyocardial ischemiasleep wake disorders

More Related Videos

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.1K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.5K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
414
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
30
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
333
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
209
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
769
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
155